



MALAYSIAN
THORACIC
SOCIETY



Optimising outcomes in *ALK+* aNSCLC:

MANAGING FIRST LINE PATIENTS ▼

Virtual webinar with live Q&A session

Thursday, 7 November 2024 at 6:00PM and 11:00PM

[Click Here to Register](#)

Dear Doctor,

It is with great pleasure that we invite you to attend a 60-minute webinar titled '**Optimising outcomes in *ALK+* aNSCLC: Managing First Line Patients**' on **Thursday, 7 November 2024 at 6:00 PM and 11:00 PM MALAYSIA TIME.**

During this webinar, we will review data from the **5-year follow-up of the CROWN trial**, including **systemic and intracranial efficacy** as well as **safety**, and the impact of these data on the use of **1L lorlatinib for the management of *ALK+* aNSCLC** in clinical practice. We will explore current approaches to pragmatic management of AEs through model case studies and share perspectives on how conversations with patients about *ALK+* aNSCLC treatments are evolving. We will also take questions from the audience during the live Q&A session.



**Dr Ibiayi
Dagogo-Jack
(USA)**



**Dr
Geoffrey
Liu
(Canada)**

Agenda

Session title

Presenter

Welcome and introductions	Ibiayi Dagogo-Jack
Lorlatinib: The CROWN study at 5 years	Ibiayi Dagogo-Jack
A patient-first approach to managing lorlatinib AEs pragmatically	Geoffrey Liu
Case study: Optimising patient communication to manage CNS AEs	Geoffrey Liu
Case study: Weight gain and hyperlipidaemia in a young, active lorlatinib patient	Ibiayi Dagogo-Jack
Live panel discussion	Both speakers
Q&A	Both speakers

We look forward to welcoming you to what promises to be an interesting and engaging event.

Drs **Ibiayi Dagogo-Jack** and **Geoffrey Liu**

1L, first-line; AE, adverse event; aNSCLC, advanced non-small cell lung cancer; *ALK*, anaplastic lymphoma kinase; CET, Central European Time; CNS, central nervous system; Q&A, question and answer.



PP-LOR-MYR-0129-24OCT2024
FOR HEALTHCARE PROFESSIONALS ONLY

Pfizer (Malaysia) Sdn Bhd 197801003134 (40131-T)
Level 10 & 11, Wisma Averis (Tower 2), Bangsar South,
No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia.
Tel: 603-22816000 Fax: 603-2281 638